Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TAS-0612 by Taiho Oncology for Solid Tumor: Likelihood of Approval
TAS-0612 is under clinical development by Taiho Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Rectal Cancer: Likelihood of Approval
(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Rectal Cancer. According...
(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Metastatic Transitional (Urothelial)...
(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Metastatic Adenocarcinoma of...
(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Rectal Cancer: Likelihood of Approval
(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Rectal Cancer. According...
TAS-0612 by Taiho Oncology for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
TAS-0612 is under clinical development by Taiho Oncology and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Squamous Non-Small Cell...
(Tipiracil hydrochloride + trifluridine) by Taiho Oncology for Esophageal Cancer: Likelihood of Approval
(Tipiracil hydrochloride + trifluridine) is under clinical development by Taiho Oncology and currently in Phase II for Esophageal Cancer. According...